近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
1.Tao Qin, Yinduo Zeng, Qianyi Lu, Xinke Zhang, Ge Qin, Qiufan Zheng,Fei Xu,Roujun Peng, Zhongyu Yuan and Shusen Wang. Nomogram Model of LNR Predicts Survival in Premenopausal.Anticancer Research 37:4575-4586(2017).(corresponding author) 2.Zheng Qiufan,Xia Wen,Lu Qianyi,Hong Ruoxi,Qin Ge,Xu Fei,Qin Tao,Shi Yanxia,Yuan Zhongyu,Wang Shusen. Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis. Breast Cancer Res Treat,2016 Nov;160(2):197-209. (corresponding author) 3.Tao Qin,Yin-duo Zeng, Ge Qin, Fei Xu, Jia-bin Lu, Wen-feng Fang, Cong Xue, Jian-hua Zhan, Xin-ke Zhang, Qiu-fan Zheng, Rou-jun Peng, Zhong-yu Yuan, Li Zhang, Shu-sen Wang.High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget, 6(32):2015,33972-81. (corresponding author) 4.Ge Qin, Fei Xu, Tao Qin, Qiufan Zheng, Dingbo Shi, Wen Xia, Yun Tian, Yanlai Tang, Jingshu Wang, Xiangshen Xiao, Wuguo Deng, Shusen Wang. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway. Oncotarget, Advance Publications 2015,1-15. (corresponding author) 5.Qiufan Zheng, Fei Xu, Man Nie, Wen Xia, Tao Qin, Ge Qin, Xin An, Cong Xue, Roujun Peng, Zhongyu Yuan, Yanxia Shi, Shusen Wang. Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer. Medicine,2015,94(40):1-9. (corresponding author) 6.Tao Qin, Zhong-Yu Yuan, Rou-Jun Peng, Bing Bai, Yin-Duo Zeng, Yan-Xia Shi, Xiao-Yu Teng,Dong-Geng Liu, Shu-Sen Wang. Clinicopathologic characteristics and prognostic factorsfor HER2-positive patients with metastatic breastcancer in southern China. Arch Med Sci 2015; 11, 3: 544–550.(corresponding author) 7.Xiao Y, Wang J, Qin Y, Xuan Y, Jia Y, Hu W, Yu W, Dai M, Li Z, Yi C, Zhao S, Li M, Du S, Cheng W, Xiao X, Chen Y, Wu T, Meng S, Yuan Y, Liu Q, Huang W, Guo W, Wang S, Deng W. Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.Oncotarget. Oncotarget. 2015 Apr 10;6(10):8046-61. (corresponding author) 8.Fu L, Shi K, Wang J, Chen W, Shi D, Tian Y, Guo W, Yu W, Xiao X, Kang T, Wang S, Huang W, Deng W. TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling. Mol Cancer,2014,13:89 (corresponding author) 9.Chen W, Qin L, Wang S, Li M, Shi D, Tian Y, Wang J, Fu L, Li Z, Guo W, Yu W, Yuan Y, Kang T, Huang W, Deng W. CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas. Mol Oncol. 2014 May;8(3):704-716 (corresponding author) 10.ZENG Yin-duo, XU Fei, QIN Tao,YANG Yan-hua, LIAO Yu-ting,Qin Ge,Wang Shu-sen. Toremifene in Postmenopausal Operable Patients with Luminal Subtype of Breast Cancer as Compared with Tamoxifen:A Retrospective Study in China. Chin J Bases Clin General Surg, 2014,21( 5):555-561(corresponding author) 11.Ma hongmin,Hu lingyu, Wang shusen.Diagnosis and Treatment for Occult Breast Cancer. Chin J Bases Clin General Surg, 2014, 21( 5):544-548(corresponding author) 12.Qin T, Yuan ZY, Peng RJ,Zeng YD,Shi YX, Teng XY,Liu DG, Bai B, Wang SS .Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: a retrospective analysis. Curr Oncol,2013, 20(4):1-9 (corresponding author) 13. Qin T, Yuan ZY, Peng RJ ,Shi YX, Teng XY,Liu DG, Bai B, Wang SS .HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negativebreast cancer patients. Onco Targets and Therapy.2013,6:341-47 (corresponding author) 14.QIN Tao, YUAN Zhong-yu, PENG Rou-jun, BAI Bing, SHI Yan-xia, TENG Xiao-yu, LIU Dong-geng, WANG Shu-sen. Efficacy and Safety of Toremifene in Young Patients with Luminal Subtype Early Breast Cancer： A Retrospective Study. JOURNAL OF SUN YAT-SEN UNIVERSITY（MEDICAL SCIENCES）,2013,34(3):402-406(corresponding author) 15.Fu ly, Chen WB, Guo W, Wang JS, Tian Y, Shi DB, Zhang XH,Qiu HJ, Xiao XS, Kang TB, Huang WL, Wang SS, Deng WG.Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth. PIOS ONE,2013,8(7):1-13 (corresponding author) 16.Gu WG, Huang Y, Yuan ZY, Peng RJ, Luo HT, He ZR, Wang SS. ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts. Asian Pac J Cancer Prev. 2013;14(3):1787-90 (corresponding author) 17.Wangbing Chen, Wei Guo, Mei Li, Dingbo Shi, Yun Tian, Zhenlin Li, Jingshu Wang, Lingyi Fu, Xiangsheng Xiao, Quentin Qiang Liu, Shusen Wang, Wenlin Huang, Wuguo Deng. Upregulation of cleavage and polyadenylation specific factor 4 in lung adenocarcinoma and its critical role for cancer cell survival and proliferation. PLoS One. 2013;8(12):e82728 (corresponding author) 18.Wang S, Shi Y, Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol. 2012,29:547-553 (first author) 19.He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T. Prognostic value of androgen receptor expression in operable triple negative breast cancer: A retrospective analysis based on a tissue microarray. Med Oncol 2012,29:406-410
京公网安备 11010802027423号